Syneron Medical's Days Sales Outstanding for the
three
months ended in Mar. 2017 was 76.71.
Syneron Medical's Days Inventory for the
three
months ended in Mar. 2017 was 143.55.
Syneron Medical's Days Payable for the
three
months ended in Mar. 2017 was 63.01.
Therefore, Syneron Medical's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2017 was 157.25.
Syneron Medical Cash Conversion Cycle Historical Data
The historical data trend for Syneron Medical's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Syneron Medical's Cash Conversion Cycle
For the Medical Devices subindustry, Syneron Medical's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syneron Medical's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Syneron Medical's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Syneron Medical's Cash Conversion Cycle falls into.
Syneron Medical Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Syneron Medical's Cash Conversion Cycle for the fiscal year that ended in Dec. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syneron Medical (NAS:ELOS) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Syneron Medical Cash Conversion Cycle Related Terms
Thank you for viewing the detailed overview of Syneron Medical's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.
Syneron Medical (Syneron Medical) Business Description
Syneron Medical Ltd., was incorporated in the State of Israel in July 2000. The Company completed its initial public offering of ordinary shares in August 2004. It designs, develops and markets aesthetic medical products based on its various technologies including its proprietary Electro-Optical Synergy, or ELOS, technology, which uses the synergy between electrical energy, including radiofrequency or RF energy, and optical energy to provide effective, safe and affordable aesthetic medical treatments. The Company's products, which it sells mainly to physicians and other practitioners, target non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin and laser-assisted lipolysis and topical skin brightening products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELOS has been successfully added to your 